18 June 2018
Visiongain’ has launched a new pharma report Inflammatory Bowel Diseases Drugs Market Report: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis
There appear to be a marked variation in the prevalence rates of IBD. Crohn's disease and ulcerative colitis are much more common in developed countries than developing ones. One of the explanations is that there may be one or more environmental factors that increase the risk of IBD, which are presumably associated with Western diets and other lifestyle factors. The incidence rate of IBD appears to have stabilised in the West. In developing countries however, the number of new cases is growing annually. This may be due to Westernisation, changes in hygiene practices or more awareness of the disease. In any case, it seems likely that incidence and prevalence of IBD will increase in many countries around the world. As a consequence, demand for IBD drugs will rise.
The lead analyst of the report commented “The inflammatory bowel diseases (IBD) drugs market will continue to be driven by rising disease incidence and more-effective non-invasive diagnosis. The IBD therapies market contains a diverse range of drugs, including biologics, which stimulate its revenue value and expand the market. Also, the incidence of IBD in emerging national markets is expected to rise as those countries become more developed.”
Leading companies featured in the report include AbbVie, Janssen, Allergan, Shire, Takeda, Johnson & Johnson, UCB, Valeant, Astellas, Celgene, Takeda.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.
14 June 2021
Rising preference for personalised medicine in developed as well as developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase NGS market concentration over the forecast period.
04 June 2021
The rising frequency of bacterial and viral diseases coupled with increased focus on immunisation programmes are two main reasons that are expected to boost the global anti-infective vaccines market’s growth in the coming years.
04 June 2021
Rising incidences of infectious diseases is one of the prime factors driving the growth of the global anti-infective agents market globally.